The Genevoyager proprietary Bac/Sf9 system demonstrates superior baculovirus stability, ensuring consistent immunogenicity and batch-to-batch consistency in vaccine production. The system enhances recombinant baculovirus generation, reduces protein degradation, and improves protein yields with minimal heterogeneity.

The Genevoyager Bac/Sf9 system has been tested in the production of human vaccines and animal vaccines, demonstrating high yield, rapid expression and scalability.

Genevoyager Bac/Sf9 system

● Genevoyager Bac/Sf9 provides a robust, cost-effective, and scalable solution for large-scale therapeutic and preventive vaccine production (up to 2000L) and allows for rapid adaptation to emerging pathogens.